CXCR2 and colorectal carcinoma: Furthermore, in animal experiments with melanoma and CRC, the up-regulated expression of tumor PD-L1 induced by CAFs was reversed after silencing CXCL5’s receptor CXCR2.This suggests that the CXCL5-CXCR2 axis may be a promising therapeutic target [84].